{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:32:02Z","timestamp":1786116722292,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10620-026-09761-5","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T14:18:03Z","timestamp":1771769883000},"page":"3073-3085","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infliximab Monotherapy Versus Infliximab and Azathioprine Combination Therapy in Patients with Ulcerative Colitis: A Cost-Effectiveness Analysis"],"prefix":"10.1007","volume":"71","author":[{"given":"Paul","family":"Dupenloup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Selnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Streett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Brandeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant E.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"9761_CR1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/s0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet (London, England). 2017;390:2769\u20132778. https:\/\/doi.org\/10.1016\/s0140-6736(17)32448-0.","journal-title":"Lancet (London, England)."},{"key":"9761_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","volume":"642","author":"L Hracs","year":"2025","unstructured":"Hracs L, Windsor JW, Gorospe J et al. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025;642:458\u2013466. https:\/\/doi.org\/10.1038\/s41586-025-08940-0.","journal-title":"Nature."},{"key":"9761_CR3","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","volume":"21","author":"MJ Buie","year":"2023","unstructured":"Buie MJ, Quan J, Windsor JW et al. Global hospitalization trends for Crohn\u2019s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses. Clin Gastroenterol Hepatol. 2023;21:2211\u20132221. https:\/\/doi.org\/10.1016\/j.cgh.2022.06.030.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9761_CR4","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","volume":"167","author":"S Singh","year":"2024","unstructured":"Singh S, Loftus EV, Limketkai BN et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167:1307\u20131343. https:\/\/doi.org\/10.1053\/j.gastro.2024.10.001.","journal-title":"Gastroenterology."},{"key":"9761_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2\u201317. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab178.","journal-title":"J Crohns Colitis."},{"key":"9761_CR6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12876-021-02028-5","volume":"21","author":"L Ruiz-Casas","year":"2021","unstructured":"Ruiz-Casas L, Evans J, Rose A et al. The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe. BMC Gastroenterol. 2021;21:456. https:\/\/doi.org\/10.1186\/s12876-021-02028-5.","journal-title":"BMC Gastroenterol."},{"key":"9761_CR7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Graff LA, Wilding H et al. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I. Inflamm Bowel Dis. 2018;24:742\u2013751. https:\/\/doi.org\/10.1093\/ibd\/izx100.","journal-title":"Inflamm Bowel Dis."},{"key":"9761_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ibd\/izy015","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Keefer L, Wilding H et al. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part II. Inflamm Bowel Dis. 2018;24:966\u2013976. https:\/\/doi.org\/10.1093\/ibd\/izy015.","journal-title":"Inflamm Bowel Dis."},{"key":"9761_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","volume":"146","author":"R Panaccione","year":"2014","unstructured":"Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.e3. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.052.","journal-title":"Gastroenterology."},{"key":"9761_CR10","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679\u20131686. https:\/\/doi.org\/10.1001\/jama.2017.16071.","journal-title":"JAMA."},{"key":"9761_CR11","doi-asserted-by":"publisher","first-page":"e001037","DOI":"10.1136\/bmjgast-2022-001037","volume":"10","author":"J Yu","year":"2023","unstructured":"Yu J, Refsum E, Wieszczy P et al. Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study. BMJ Open Gastroenterol. 2023;10:e001037. https:\/\/doi.org\/10.1136\/bmjgast-2022-001037.","journal-title":"BMJ Open Gastroenterol."},{"key":"9761_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2036.2011.04682.x","volume":"34","author":"C Steenholdt","year":"2011","unstructured":"Steenholdt C, Svenson M, Bendtzen K et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:51\u201358. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04682.x.","journal-title":"Aliment Pharmacol Ther."},{"key":"9761_CR13","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","volume":"374","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617\u20131625. https:\/\/doi.org\/10.1016\/S0140-6736(09)61302-7.","journal-title":"Lancet."},{"key":"9761_CR14","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda G, Jharap B, Neeraj N et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin. Transl. Gastroenterol. 2016;7:e135. https:\/\/doi.org\/10.1038\/ctg.2015.63.","journal-title":"Clin. Transl. Gastroenterol."},{"key":"9761_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s10620-022-07789-x","volume":"68","author":"G Syal","year":"2023","unstructured":"Syal G, Melmed GY, Almario CV et al. Azathioprine withdrawal is cost-effective in patients with Crohn\u2019s disease in remission on infliximab and azathioprine. Dig Dis Sci. 2023;68:404\u2013413. https:\/\/doi.org\/10.1007\/s10620-022-07789-x.","journal-title":"Dig Dis Sci."},{"key":"9761_CR16","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","volume":"120","author":"DT Rubin","year":"2025","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA et al. ACG clinical guideline update: ulcerative colitis in adults. Off. J. Am. Coll. Gastroenterol. 2025;120:1187. https:\/\/doi.org\/10.14309\/ajg.0000000000003463.","journal-title":"Off. J. Am. Coll. Gastroenterol."},{"key":"9761_CR17","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s10620-024-08802-1","volume":"70","author":"P Dupenloup","year":"2025","unstructured":"Dupenloup P, Zhou M, Dizon MP et al. Therapeutic drug monitoring in patients with ulcerative colitis on infliximab: a cost-effectiveness analysis. Dig Dis Sci. 2025;70:728\u2013737. https:\/\/doi.org\/10.1007\/s10620-024-08802-1.","journal-title":"Dig Dis Sci."},{"key":"9761_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40273-019-00837-x","volume":"37","author":"F Alarid-Escudero","year":"2019","unstructured":"Alarid-Escudero F, Krijkamp EM, Pechlivanoglou P et al. A need for change! A coding framework for improving transparency in decision modeling. PharmacoEconomics. 2019;37:1329\u20131339. https:\/\/doi.org\/10.1007\/s40273-019-00837-x.","journal-title":"PharmacoEconomics."},{"key":"9761_CR19","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u20132476. https:\/\/doi.org\/10.1056\/NEJMoa050516.","journal-title":"N Engl J Med."},{"key":"9761_CR20","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1097\/MIB.0000000000000115","volume":"20","author":"A Armuzzi","year":"2014","unstructured":"Armuzzi A, Pugliese D, Danese S et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2014;20:1368\u20131374. https:\/\/doi.org\/10.1097\/MIB.0000000000000115.","journal-title":"Inflamm Bowel Dis."},{"key":"9761_CR21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","volume":"17","author":"JF Colombel","year":"2019","unstructured":"Colombel JF, Adedokun OJ, Gasink C et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis. Clin Gastroenterol Hepatol. 2019;17:1525-1532.e1. https:\/\/doi.org\/10.1016\/j.cgh.2018.09.033.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9761_CR22","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1097\/MIB.0000000000001223","volume":"23","author":"X Roblin","year":"2017","unstructured":"Roblin X, Boschetti G, Duru G et al. Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study. Inflamm Bowel Dis. 2017;23:2048\u20132053. https:\/\/doi.org\/10.1097\/MIB.0000000000001223.","journal-title":"Inflamm Bowel Dis."},{"key":"9761_CR23","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/s0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet (London, England). 2022;399:2113\u20132128. https:\/\/doi.org\/10.1016\/s0140-6736(22)00581-5.","journal-title":"Lancet (London, England)."},{"key":"9761_CR24","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl. J. Med. 2019;381:1201\u20131214. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl. J. Med."},{"key":"9761_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/annrheumdis-2016-209389","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer LK, Galloway JB, Lunt M et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2017;76:497\u2013503. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209389.","journal-title":"Ann Rheum Dis."},{"key":"9761_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","volume":"145","author":"N Khan","year":"2013","unstructured":"Khan N, Abbas AM, Lichtenstein GR et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145:1007-1015.e3. https:\/\/doi.org\/10.1053\/j.gastro.2013.07.035.","journal-title":"Gastroenterology."},{"key":"9761_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/ecco-jcc\/jjad177","volume":"18","author":"M Muller","year":"2024","unstructured":"Muller M, Bros\u00e9us J, Guilloteau A et al. Lymphoma in patients with inflammatory bowel disease: a multicentre collaborative study between GETAID and LYSA. J Crohns Colitis. 2024;18:533\u2013539. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad177.","journal-title":"J Crohns Colitis."},{"key":"9761_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2482136","author":"M Garg","year":"2025","unstructured":"Garg M, Satija A, Song Y et al. Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data. Leuk Lymphoma. 2025. https:\/\/doi.org\/10.1080\/10428194.2025.2482136.","journal-title":"Leuk Lymphoma."},{"key":"9761_CR29","doi-asserted-by":"publisher","first-page":"e35833","DOI":"10.1002\/cncr.35833","volume":"131","author":"RL Sherman","year":"2025","unstructured":"Sherman RL, Firth AU, Henley SJ et al. Annual report to the nation on the status of cancer, featuring state-level statistics after the onset of the COVID-19 pandemic. Cancer. 2025;131:e35833. https:\/\/doi.org\/10.1002\/cncr.35833.","journal-title":"Cancer."},{"key":"9761_CR30","first-page":"1","volume":"58","author":"E Arias","year":"2010","unstructured":"Arias E. United States life tables, 2006. National Vital Statistics Reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2010;58:1\u201340.","journal-title":"National Vital Statistics Reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System."},{"key":"9761_CR31","unstructured":"Agency for Healthcare Research and Quality. Number of people in thousands, United States, 1996\u20132018. https:\/\/meps.ahrq.gov\/mepstrends\/hc_use. Accessed on 2 May 2025."},{"key":"9761_CR32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/apt.12844","volume":"40","author":"C Nordenvall","year":"2014","unstructured":"Nordenvall C, Ekbom A, Bottai M et al. Mortality after total colectomy in 3084 patients with inflammatory bowel disease: a population-based cohort study. Alimentary Pharmacol. Therap. 2014;40:280\u2013287. https:\/\/doi.org\/10.1111\/apt.12844.","journal-title":"Alimentary Pharmacol. Therap."},{"key":"9761_CR33","unstructured":"IBM Micromedex\u00ae Red Book, Truven Health Analytics (2025). Accessed on June 16, 2025."},{"key":"9761_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-4733.2009.00663.x","volume":"13","author":"JW Hay","year":"2010","unstructured":"Hay JW, Smeeding J, Carroll NV et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report\u2013Part I. Value Health. 2010;13:3\u20137. https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00663.x.","journal-title":"Value Health."},{"key":"9761_CR35","unstructured":"Center for Medicare & Medicaid Services. Physician Fee Schedule Search."},{"key":"9761_CR36","unstructured":"Center for Medicare & Medicaid Services. Clinical Laboratory Fee Schedule. Accessed on June 16, 2025."},{"key":"9761_CR37","doi-asserted-by":"publisher","first-page":"otab029","DOI":"10.1093\/crocol\/otab029","volume":"3","author":"S Weissman","year":"2021","unstructured":"Weissman S, Sharma S, Fung BM et al. Increased mortality and healthcare costs upon hospital readmissions of ulcerative colitis flares: a large population-based cohort study. Crohn\u2019s Colitis 360. 2021;3:otab029. https:\/\/doi.org\/10.1093\/crocol\/otab029.","journal-title":"Crohn\u2019s Colitis 360."},{"key":"9761_CR38","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/DCR.0b013e3181b327a6","volume":"52","author":"SD Holubar","year":"2009","unstructured":"Holubar SD, Long KH, Loftus EV et al. Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota. Dis Colon Rectum. 2009;52:1815\u20131823. https:\/\/doi.org\/10.1007\/DCR.0b013e3181b327a6.","journal-title":"Dis Colon Rectum."},{"key":"9761_CR39","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.surg.2016.10.019","volume":"161","author":"AL Chang","year":"2017","unstructured":"Chang AL, Kim Y, Ertel AE et al. Case mix-adjusted cost of colectomy at low-, middle-, and high-volume academic centers. Surgery. 2017;161:1405\u20131413. https:\/\/doi.org\/10.1016\/j.surg.2016.10.019.","journal-title":"Surgery."},{"key":"9761_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10198-009-0199-5","volume":"11","author":"YS Punekar","year":"2010","unstructured":"Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur. J Health Econ. 2010;11:67\u201376. https:\/\/doi.org\/10.1007\/s10198-009-0199-5.","journal-title":"Eur. J Health Econ."},{"key":"9761_CR41","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s11136-012-0220-9","volume":"22","author":"R Crott","year":"2013","unstructured":"Crott R, Versteegh M, Uyl-de-Groot C. An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Qual Life Res. 2013;22:1045\u20131054. https:\/\/doi.org\/10.1007\/s11136-012-0220-9.","journal-title":"Qual Life Res."},{"key":"9761_CR42","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jval.2012.05.003","volume":"15","author":"R Ara","year":"2012","unstructured":"Ara R, Wailoo A. Using health state utility values in models exploring the cost-effectiveness of health technologies. Value Health. 2012;15:971\u2013974. https:\/\/doi.org\/10.1016\/j.jval.2012.05.003.","journal-title":"Value Health."},{"key":"9761_CR43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989x06290497","volume":"26","author":"J Hanmer","year":"2006","unstructured":"Hanmer J, Lawrence WF, Anderson JP et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med. Dec. Mak. 2006;26:391\u2013400. https:\/\/doi.org\/10.1177\/0272989x06290497.","journal-title":"Med. Dec. Mak."},{"key":"9761_CR44","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093\u20131103. https:\/\/doi.org\/10.1001\/jama.2016.12195.","journal-title":"JAMA."},{"key":"9761_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/1475-6773.12612","volume":"53","author":"A Dunn","year":"2018","unstructured":"Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv. Res.. 2018;53:175\u2013196. https:\/\/doi.org\/10.1111\/1475-6773.12612.","journal-title":"Health Serv. Res.."},{"key":"9761_CR46","unstructured":"Agency for Healthcare Research and Quality. Using appropriate price indices for expenditure comparisons. www.meps.ahrq.gov\/about_meps\/Price_Index.shtml. Accessed on 2 May 2025."},{"key":"9761_CR47","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989x12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group\u20136. Med. Dec. Mak. 2012;32:722\u2013732. https:\/\/doi.org\/10.1177\/0272989x12458348.","journal-title":"Med. Dec. Mak."},{"key":"9761_CR48","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1177\/0272989x15605091","volume":"36","author":"JD Goldhaber-Fiebert","year":"2016","unstructured":"Goldhaber-Fiebert JD, Jalal HJ. Some health states are better than others: using health state rank order to improve probabilistic analyses. Med. Dec. Mak. 2016;36:927\u2013940. https:\/\/doi.org\/10.1177\/0272989x15605091.","journal-title":"Med. Dec. Mak."},{"key":"9761_CR49","unstructured":"A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases | PLOS One. https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0145087. Accessed on Sept 8, 2025."},{"key":"9761_CR50","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s11136-012-0220-9","volume":"22","author":"R Crott","year":"2013","unstructured":"Crott R, Versteegh M, Uyl-de-Groot C. An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Qual Life Res. 2013;22:1045\u20131054. https:\/\/doi.org\/10.1007\/s11136-012-0220-9.","journal-title":"Qual Life Res."},{"key":"9761_CR51","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/13696998.2017.1285779","volume":"20","author":"A Afzali","year":"2017","unstructured":"Afzali A, Ogden K, Friedman ML et al. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting. J Med Econ. 2017;20:409\u2013422. https:\/\/doi.org\/10.1080\/13696998.2017.1285779.","journal-title":"J Med Econ."},{"key":"9761_CR52","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1097\/MIB.0000000000001223","volume":"23","author":"X Roblin","year":"2017","unstructured":"Roblin X, Boschetti G, Duru G et al. Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study. Inflamm Bowel Dis. 2017;23:2048\u20132053. https:\/\/doi.org\/10.1097\/MIB.0000000000001223.","journal-title":"Inflamm Bowel Dis."},{"key":"9761_CR53","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257\u201365. https:\/\/doi.org\/10.1053\/j.gastro.2011.10.032.","journal-title":"Gastroenterology."},{"key":"9761_CR54","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41395-018-0162-0","volume":"113","author":"N Narula","year":"2018","unstructured":"Narula N, Peerani F, Meserve J et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113:1345. https:\/\/doi.org\/10.1038\/s41395-018-0162-0.","journal-title":"Am J Gastroenterol."},{"key":"9761_CR55","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/ecco-jcc\/jjy039","volume":"12","author":"K Papamichael","year":"2018","unstructured":"Papamichael K, Vajravelu RK, Vaughn BP et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohn\u2019s Colitis. 2018;12:804\u2013810. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy039.","journal-title":"J Crohn\u2019s Colitis."},{"key":"9761_CR56","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1080\/10428194.2025.2482136","volume":"66","author":"M Garg","year":"2025","unstructured":"Garg M, Satija A, Song Y et al. Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data. Leuk Lymphoma. 2025;66:1447\u20131456. https:\/\/doi.org\/10.1080\/10428194.2025.2482136.","journal-title":"Leuk Lymphoma."},{"key":"9761_CR57","doi-asserted-by":"publisher","first-page":"e35833","DOI":"10.1002\/cncr.35833","volume":"131","author":"RL Sherman","year":"2025","unstructured":"Sherman RL, Firth AU, Henley SJ et al. Annual report to the nation on the status of cancer, featuring state-level statistics after the onset of the COVID-19 pandemic. Cancer. 2025;131:e35833. https:\/\/doi.org\/10.1002\/cncr.35833.","journal-title":"Cancer."},{"key":"9761_CR58","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","volume":"152","author":"JS Hyams","year":"2017","unstructured":"Hyams JS, Dubinsky MC, Baldassano RN et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152:1901-1914.e3. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.004.","journal-title":"Gastroenterology."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09761-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09761-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09761-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:54:20Z","timestamp":1786017260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09761-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["9761"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09761-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}